Previous Article | Next Article 
Journal of Virology, March 1999, p. 1949-1955, Vol. 73, No. 3
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Structure of Adeno-Associated Virus Vector DNA
following Transduction of the Skeletal Muscle
Nathalie
Vincent-Lacaze,1
Richard O.
Snyder,2
Régis
Gluzman,1
Delphine
Bohl,3
Catherine
Lagarde,2 and
Olivier
Danos1,*
Gene Therapy Program, Genethon III, CNRS URA
1922, Evry,1 and
Laboratoire Retrovirus
et Transfert Génétique, Institut Pasteur,
Paris,3 France, and
Cell Genesys, Foster
City, California2
Received 16 November 1998/Accepted 30 November 1998
 |
ABSTRACT |
The skeletal muscle provides a very permissive physiological
environment for adeno-associated virus (AAV) type 2-mediated gene
transfer. We have studied the early steps leading to the establishment
of permanent transgene expression, after injection of recombinant AAV
(rAAV) particles in the quadriceps muscle of mice. The animals received
an rAAV encoding a secreted protein, murine erythropoietin (mEpo),
under the control of the human cytomegalovirus major immediate-early
promoter and were sacrificed between 1 and 60 days after injection. The
measurement of plasma Epo levels and of hematocrits indicated a
progressive increase of transgene expression over the first 2 weeks,
followed by a stabilization at maximal plateau values. The rAAV
sequences were analyzed by Southern blotting following neutral or
alkaline gel electrophoresis of total DNA from injected muscles. While
a high number of rAAV sequences were detected during the first 5 days
following the injection, only a few percent of these sequences was
retained in the animals analyzed after 2 weeks, in which transgene
expression was maximal. Double-stranded DNA molecules resulting from de
novo second-strand synthesis were detected as early as day 1, indicating that this crucial step of AAV-mediated gene transfer is
readily accomplished in the muscle. The templates driving stable gene expression at later time points are low in copy number and structured as high-molecular-weight concatemers or interlocked circles. The presence of the circular form of the rAAV genomes at early time points
suggests that the molecular transformations involved in the formation
of stable concatemers may involve a rolling-circle type of DNA replication.
 |
INTRODUCTION |
Human adeno-associated virus (AAV)
type 2 is a nonpathogenic parvovirus, whose 4.7-kb genome consists in
two 145-nucleotide inverted terminal repeats (ITRs) and two genes,
rep, encoding several proteins involved in the virus life
cycle, and cap, encoding structural virion proteins
(4). In infected cells, the incoming AAV single-stranded DNA
(ssDNA) is converted into a double-stranded (ds) transcriptional
template. Further steps in the productive viral replication require
functions provided by a helper adenovirus or herpesvirus. In the
absence of helper functions, the AAV dsDNA is able to integrate at
specific sites into the human genome, most frequently on chromosome 19q
(21). It then can persist indefinitely in a latent state
until mobilized and rescued by a helper virus superinfection. This
site-specific integration involves the Rep 68/78 proteins
(37), which are thought to initiate the process by bridging
genomic and viral sequences and nicking one strand in the ds AAV
genome. Integration per se probably involves cellular recombination
pathways. The absence of known pathogenicity together with this
capacity for integrating in the host genome has rendered recombinant
AAV (rAAV) vectors attractive for gene therapy prospects. The ITRs from
the AAV genome are the only viral sequences required in cis
to generate rAAV vectors. Recombinant constructs containing two ITRs
bracketing a gene expression cassette of up to 4.5 kb are converted
into an ssDNA vector genome and packaged into AAV particles, in the
presence of the AAV rep and cap gene products and
helper functions from an adenovirus (32).
The terminally differentiated and postmitotic muscle cells provide a
highly permissive environment for rAAV-mediated gene transfer, and
long-term expression in animal experiments has been obtained previously
(7, 13, 15, 18, 25, 34, 38). The mechanism by which rAAV
genomes become stabilized in the muscle fiber nuclei is still unclear.
This establishment phase may take several weeks, as suggested by the
progressive increase in gene expression that takes place following gene
transfer (14, 18, 26, 33, 34). A consequence of this
peculiar mode of expression may be the weak and transient immune
response observed even with transgenes whose products are known to be
strongly immunogenic in the context of an adenoviral vector
(16).
Here, we have sought to characterize the status of vector DNA during
this establishment phase. We have injected an rAAV encoding the murine
erythropoietin (mEpo) into the muscles of mice and analyzed both
transgene expression and rAAV DNA status at different time points. Our
analysis indicates that a series of molecular transformations of rAAV
DNA occur over the first month following gene transfer. The nature of
the molecular intermediates identified here provides clues for the
definition of a maintenance mechanism for the rAAV genome in the
transduced muscle.
 |
MATERIALS AND METHODS |
rAAV vector production.
pSSV9-MD-mEPO was described
previously (34). It contains the mEpo cDNA under the control
of the cytomegalovirus (CMV) immediate-early promoter and intron 2 and
3' untranslated region from the human
-globin gene (Fig. 1). rAAV
AAV-MD-mEpo was prepared as described elsewhere (35). The
titers of the rAAV preparations were determined by dot blot
hybridization (1012 physical particles/ml) and by
limiting-dilution infections. The stocks were determined to be free of
detectable contamination by adenovirus and by replication-competent AAV
(less than 1 wild-type AAV/108 rAAVs).
Animal studies.
Eight-week-old BALB/c mice were anesthetized
with sodium barbitol (95 mg/kg of body weight) and injected in the
quadriceps muscle with a single dose of 30 µl (2.7 × 1010 particles) of AAV-MD-mEpo. Two animals were sacrificed
1, 2, 7, 14, 30, and 60 days following injection (experiment 1), and three animals were sacrificed 1, 2, 3, 4, 5, 6, and 7 days following injection (experiment 2). For each animal, both quadriceps were taken
and frozen in liquid nitrogen. Blood samples were collected into
EDTA-coated tubes, by punction of the retroorbital sinus, with
heparin-coated capillaries. Detection of mEpo was carried out on 20 µl of plasma in a total volume of 200 µl by a sandwich radioimmunoassay (I-125 EPO COATRIA; BioMerieux, Marcy l'Etoile, France). Each measurement was carried out in duplicate. For each assay,
a standard curve was established by measuring the binding of total
activity of standards included in the kit, ranging from 5 to 900 mU of
Epo per ml. Since we used 10-fold-diluted samples and the first point
of the standard curve is at 5 mU/ml, only values greater than 50 mU/ml
were considered accurate. Transgene expression was also indirectly
estimated by measuring the hematocrit (reflecting the level of
circulating erythrocytes) by a microhematocrit method (20).
DNA analysis.
Total genomic DNA was isolated from injected
quadriceps or control quadriceps by a standard procedure
(3). Briefly, the muscle was frozen in liquid nitrogen,
crushed with a mortar and pestle, and digested for 18 h at 50°C
in a solution containing 100 mM NaCl, 10 mM Tris-HCl (pH 8), 25 mM EDTA
(pH 8), and 0.5% sodium dodecyl sulfate, and 0.1 mg of proteinase K
per ml. After two phenol-chloroform-isoamyl alcohol extractions and one
chloroform extraction, the DNA was ethanol precipitated for 18 h
at
20°C in 3.5 M ammonium acetate and resuspended in a solution
consisting of 10 mM Tris-HCl (pH 8) and 0.1 mM EDTA. Standard Southern
blot analysis was performed as follows. Four or eight micrograms of DNA
was digested with restriction endonuclease for 16 h,
electrophoresed through an 0.8% agarose gel, transferred onto a nylon
membrane, and hybridized to a radiolabeled mEpo cDNA probe or to a
probe complementary to the CMV immediate-early promoter
(XbaI/HindIII restriction fragment of
pSSV9-MD-mEPO). Filters were exposed for 1 to 7 days and analyzed on a
Storm scanner (Molecular Dynamics). The ratio of viral genomes per
haploid host genome was assessed on XbaI blots with the
ImageQuant program by measuring the ratio of the hybridization signal
from the vector internal 2.7-kb fragment to the hybridization signal
from the endogenous Epo gene.
293 cells (American Type Culture Collection) were coinfected with
AAV-MD-mEpo (multiplicity of infection of 5) and an adenovirus with E1
deleted (Ad dl324) (multiplicity of infection of 5). Cells were
harvested 48 h after infection and lysed for total DNA extraction by a standard procedure (3). Active rAAV replication in
these cells was assessed by Southern blot detection of ds species after nondenaturing gel electrophoresis. Alkaline gel electrophoresis was
performed on 4 µg of HindIII-digested total DNA either
from AAV-MD-Epo-injected muscles or from AAV-MD-Epo-infected 293 cells, as a control. Samples were loaded on a 25-cm-long denaturing gel as
described elsewhere (31) and run for 4 h at 50 V. After
alkali blotting, the filter was hybridized with the CMV promoter probe. We used PvuII-BglII- or
PvuII-HindIII-purified restriction fragments from pSSV9-MD-mEPO as size markers (2,138- and 993-base-long molecules, respectively). DNA extracted from a purified preparation of an rAAV Neo
green fluorescent protein (3,400 bases) (40) was used as a
size marker for the full-length rAAV ssDNA.
 |
RESULTS |
An rAAV vector encoding mEpo (AAV-MD-mEpo) (34) was
injected as a single intramuscular dose (2.7 × 1010
particles) into two groups of adult immunocompetent mice. The first
group (n = 12) was studied over a 60-day period, and
the second group (n = 21) was used to examine the
events taking place during the first week following gene transfer.
Blood was collected at the time of sacrifice, and the transgene
activity was documented, either directly by measuring serum Epo levels
or indirectly by assessing the hematocrit. Genomic DNA was prepared
from the injected muscle, and the vector sequences were analyzed by
Southern blotting.
In the first experimental group, an increase in mEpo plasma levels
(Table 1) was first detected on day 7 (165-mU/ml average) and reached a plateau on day 14 (490-mU/ml
average). This represented a 20-fold increase compared to the baseline
value in noninjected animals. As a consequence of these elevated Epo
levels, the hematocrit of animals sacrificed after day 7 was high, with
values around 85% reached on day 30. The analysis of the second group
indicated that the Epo transgene expression can be detected with
confidence (i.e., Epo levels over 50 mU/ml [see Materials and
Methods]) as early as day 4, with an effect on the hematocrit on day 6 (Table 2). Altogether, these measurements
showed that following rAAV injection in the muscle, there was a
progressive transgene expression over the first 2 weeks, before maximal
stable values were reached.
The progressive appearance of transgene expression in rAAV-transduced
tissues may be related to the kinetics of synthesis of ds forms of the
vector DNA, suitable for transcription. In order to examine the
formation of ds transcription templates, total DNA was extracted from
the injected muscles and analyzed by Southern blotting. Digestion with
XbaI releases a 2.7-kb DNA fragment internal to the vector
(Fig. 1a). The intensity of this fragment
is a measure of the total amount of rAAV dsDNA in the muscle DNA
preparation. Digestion with BclI, an enzyme that does not
cut within the rAAV genome, was used to analyze the status of the input
vector DNA at different time points (Fig. 1c). At days 1 and 2, a
strong signal with an apparent size of 1.3 kb was present in both
XbaI and BclI digests. Since this band was not
affected by any restriction enzyme used (including NheI and BglII [see Fig. 4b]), we attributed it to the input ss
rAAV genome, according to previous reports (7, 13, 24, 34).
This signal progressively decreased thereafter and was almost
undetectable on day 60. Unexpectedly, the 2.7-kb XbaI
fragment indicative of the presence of ds rAAV genomes was detected
from day 1. It persisted up to 60 days (Fig. 1b), and there was an
inverse relationship between its intensity and the amount of transgene
expression. The XbaI analysis was used to quantify the
amount of ds rAAV genome per haploid mouse genome (Table 1). On day 7, only 1 to 3% of the signal detected at day 2 remained (approximately
0.8 versus 28 copies/haploid genome). On day 60, the rAAV internal
fragment was detectable at a level of 0.3 copy/haploid genome.
Digestion with BclI resulted in a signal at 3.1 kb, the
expected size for the linear ds monomer. This band was intense on days
1 and 2, decreased until day 30, and was no longer detected in animals sacrificed at day 60 (Fig. 1c), even when blots were overexposed (data
not shown). Two additional bands at 3.5 and 1.9 kb were also detected
from day 1 to day 30 and were no longer seen on day 60. These three
forms of the rAAV genome were further analyzed in the second series of
animals (see below). These data indicated that the ds rAAV genomes
detected in the XbaI digest on day 60 had been converted to
higher-molecular-weight forms that were not resolved in the
BclI digest. The low intensity of the rAAV-specific hybridization signal (0.3 copy/genome) precluded the detection of a
smear, corresponding to randomly integrated vector sequences, or to
large concatemers of the rAAV genome. When a single-cut enzyme
(BglII) was used on DNA obtained on day 30, only a 3.1-kb monomer-size band was observed, indicating that most vector genomes were structured either as head-to-tail repeats or possibly as complexes
of interlocked circles (Fig. 2, lane 3).

View larger version (52K):
[in this window]
[in a new window]
|
FIG. 1.
Southern blot analysis of the AAV-MD-mEpo AAV genomes in
injected muscles. (a) Positions of restriction sites and probe (Epo
cDNA) in AAV-MD-mEpo. Digestion with XbaI releases a 2.7-kb
DNA fragment internal to the vector. BclI does not cut in
the vector. AAV ITRs are represented as shaded boxes. CMV,
immediate-early promoter from the human CMV; IVS, second intron from
the human -globin gene; polyA, untranslated region from the human
-globin gene. (b) Time course detection of AAV-MD-mEpo DNA: Southern
blot analysis of XbaI-digested total DNA (4 µg) from
injected muscles of animals sacrificed on day (d) 2 to day 60 after
injection (experiment 1). Sacrifice dates are indicated above the
lanes. Control, DNA from a noninjected muscle (4 µg) spiked with
plasmid pSSV9-MD-mEpo (0.5 copy/haploid genome) and cut by
XbaI. Apparent sizes of the hybridizing bands are indicated
in kilobases on the right of the autoradiogram. The mEpo cDNA probe
detects an endogeneous 6.5-kb fragment in the mouse genome. (c)
Southern blot analysis of BclI-digested genomic DNA (8 µg)
from injected muscles (day [d] 1 to day 60 after injection). Control,
BclI-digested DNA from a noninjected muscle (8 µg).
Apparent sizes (kilobases) of the different fragments are indicated on
the right of the gel. The mEpo cDNA probe detects an endogenous 12-kb
fragment in the mouse genome.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 2.
Detection of head-to-tail tandem by Southern blot
analysis (mEpo cDNA probe). Each lane contains 8 µg of total DNA from
an injected muscle (day 30 after injection) digested with
BclI (lane 1), XbaI (lane 2), or BglII
(lane 3). The mEpo cDNA probe detects in each lane an endogenous
fragment (12, 6.5, and 4.5 kb, respectively). Numbers at right indicate
size in kilobases.
|
|
The same analysis of genomic DNA prepared from rAAV-transduced muscles
was performed on the second group of animals sacrificed between days 1 and 7. The same profiles as in experiment 1 were obtained when the DNA
was digested by XbaI or BclI (data not shown). A
very intense signal corresponding to over 20 copies of the 3.1-kb monomer per haploid genome was detected in samples from animals sacrificed between days 1 and 4 (Table 2). A 10-fold-weaker signal was
present at day 4, a situation similar to the one observed at day 7 in
the previous experiment. In order to verify whether the ds monomers
arose from second-strand synthesis or from the annealing of
complementary positive- and negative-strand ssDNA equally present in
the AAV population (5), we performed alkaline gel
electrophoresis of HindIII-digested DNA from injected
quadriceps of five animals sacrificed 1 (n = 2), 2 (n = 1), and 3 (n = 2) days after injection.
As depicted in Fig. 3a,
HindIII cuts at position 993 in the rAAV genome. After
digestion, alkaline gel separation, and blot hybridization with a CMV
promoter probe, the ds forms resulting from complementary-strand
reannealing or from negative-strand synthesis (closed right end, Fig.
3a) are expected to yield the same band as the control pSSV9-MD-Epo
plasmid cut with PvuII and HindIII (Fig. 3b,
lane 3). In contrast, the ds species resulting from positive-strand
synthesis and containing a closed terminal hairpin (closed left end,
Fig. 3a) are expected to yield the same band as the control
pSSV9-MD-Epo plasmid cut with PvuII and
HindIII (Fig. 3b, lane 3). In contrast, the ds species
resulting from positive-strand synthesis and containing a closed
terminal hairpin (closed left end, Fig. 3a) are expected to be retarded
on the alkaline gel. Both bands were indeed detected in a control DNA sample prepared from 293 cells coinfected with AAV-MD-mEpo and an
E1-deleted adenovirus which contained newly synthesized ds forms (Fig.
3b, lane 4). The third, slowly migrating band corresponded to the input
ss genome (Fig. 3b, lane 1). Figure 3b shows that these three molecular
species were detected in all samples (lanes 5 to 10). In particular,
the presence of the middle band indicated that a fraction of the ds
monomers observed as early as day 1 arose from second-strand synthesis.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Southern blot analysis of the vector DNA after alkaline
gel electrophoresis. (a) Positions of restriction sites and probe (CMV
promoter) in pSSV9-MD-mEpo. The different species expected to be
detected in the analysis are represented below. Three different
fragments are expected upon HindIII digestion of these
forms: (1) undigested ssDNA, (2) fragment from closed-left-end ds
species (ds forms resulting from the synthesis of positive strand), and
(3) fragment either from reannealed ds species or from closed-right-end
species (ds forms resulting from synthesis of negative strand). IVS,
second intron from the human -globin gene. (b) Southern blot
following alkaline gel electrophoresis of
HindIII-digested total muscle DNA (4 µg) from animals
sacrificed on day 1 (lanes 5 and 6 correspond to two different DNA
samples from the same injected muscle split prior to the extraction
process, and lane 7 corresponds to a second animal), day 2 (one animal,
lane 8), and day 3 (two animals, lanes 9 and 10). Lane 4 contains DNA
from 293 cells coinfected with AAV-MD-mEpo and a helper adenovirus as a
control for second-strand synthesis. Lanes 1 to 3 contain the following
size markers: purified DNA from rAAV green fluorescent protein Neo
particles (lane 1), PvuII/BglII fragment from
pSSV9-MD-mEpo (lane 2), and PvuII/HindIII
fragment of pSSV9-MD-mEpo (lane 3). Sizes in bases are indicated on the
left.
|
|
As mentioned above, two additional, rAAV-specific bands with apparent
sizes of 1.9 and 3.5 kb were detected in early samples treated with
BclI. In order to elucidate the nature of the 3.5-kb band,
the total DNA from an animal sacrificed 1 day after injection was
analyzed with BglII and NheI, two enzymes that
cut the vector DNA once (Fig. 4a).
Digestion with BglII (Fig. 4b, lane 3) yielded the expected
2.1-kb fragment from the linear monomer and eliminated the 3.5-kb
species present in the BclI digest (Fig. 4b, lane 1). The
signal remaining at 3.1 kb in the BglII digest was
eliminated in the double digest with BglII and
NheI (Fig. 4b, lane 2), in which a 2.8-kb fragment appeared.
The presence of this fragment indicated that the 3.1-kb band in the
BglII digest was a permuted form of the monomeric genome.
Such a permutation can originate from either head-to-tail concatemers
or circular forms of the genome. The fact that the 3.5-kb band
disappeared in the BglII digest suggests that this band
represents such circular forms.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Southern blot analysis of rAAV DNA species in an animal
sacrificed 1 day after injection. (a) Positions of restriction sites
and probe (CMV promoter) in MD-AAV-mEpo (see legend to Fig. 1a). IVS,
second intron from the human -globin gene. (b) Four micrograms of
total DNA was digested by BclI (lane 1), BglII
(lane 3), or both BglII and NheI (lane 2). The
diagram on the left indicates the deduced structure of the 3.5- and
3.1-kb DNA species: circular monomeric form (I), ds monomeric form
(linear) (II), or linearized circular form and/or digested head-to-tail
concatemer (III). The shaded boxes indicate the ITRs.
|
|
The data shown in Fig. 4 also indicated that the 1.9-kb band was
partially resistant to digestion by BglII (Fig. 4b). This suggests the presence of several comigrating molecular species. They
possibly correspond to partially ds forms, produced by pausing of the
second-strand DNA synthesis: depending on which strand is used as the
DNA polymerase template, pauses will produce intermediates whose ds
portion may or may not contain a BglII site. Further experiments will be needed to validate this hypothesis.
 |
DISCUSSION |
Permissiveness for rAAV-mediated gene transfer varies broadly
among different tissues or cell types. For instance, differentiated tissues such as brain (22), retina (14), liver
(19, 33), and skeletal muscle (7, 13, 15, 18, 25, 34,
38) are naturally permissive, whereas primary cell cultures or
bone-marrow-derived cells (27) have been more difficult to
transduce. Susceptibility to rAAV transduction may in some cases simply
be related to the efficiency of vector entry. In this respect, cell
surface levels of heparan sulfate, which acts as an attachment
receptor, have been shown to be important (36). Gene
expression following transduction is also highly dependent on the
presence of the appropriate cellular environment. The cellular DNA
synthesis machinery is needed to convert the vector ssDNA into a ds
form that can serve as a transcription template (11, 12).
Functions expressed by a coinfecting helper adenovirus, as well as
various genotoxic treatments (1, 2, 29), are known to
enhance this process. Cellular permissiveness has been correlated
elsewhere with the phosphorylation status of a protein able to bind the
D sequence on the AAV genome (28). Here, we have undertaken
a time course analysis of transgene expression and vector genome status
in the permissive context of the skeletal muscle. We observe that,
following injection, high levels of rAAV genomes are found in total DNA
preparations from days 1 to 5. The input ssDNA is retained for several
days, and in some animals, it is still detectable at day 60. It is
possible that this vector DNA comes from particles trapped by the
heparan sulfate in the extracellular matrix surrounding muscle fibers
(8) and that these vector particles continuously initiate
transduction events over several days.
Our measurements indicate that transgene expression can be detected as
early as day 4. This is consistent with the efficient conversion of the
input ssDNA into dsDNA that we observed in DNA samples analyzed between
days 1 and 3. Yet, most of the vector DNA originally present ends up
being eliminated. Around day 5, the number of rAAV genome copies is
dramatically reduced, and only 1 to 3% of the original amount of
genetic material is retained after day 7. Unexpectedly, the clearance
of most of the vector DNA is concomitant with the elevation of
expression levels. Therefore, only a few genomes are stabilized and
established as transcriptionally active. Monomers are not detectable on
day 60, and our analysis suggests that most of the remaining genomes
exist as high-molecular-weight species. These can be either
head-to-tail concatemers as reported previously (7, 13, 34,
38) or, alternatively, interlocked circular forms of the genome.
The formation of high-molecular-weight structures appears to be key in
the establishment of a stable genetic modification, but the underlying
mechanism remains unclear. It is interesting to note that multimers
which can be directly synthesized from a linear ss AAV template with
the ITR priming structure are expected to be in an inverted
configuration (head to head or tail to tail) (39). The
predominance of direct repeats suggests that another mechanism is
actually involved in concatemer formation. Here, we observe the
presence of circular monomers which are formed very early after
transduction and progressively disappear thereafter. This is in
agreement with a recent report where Duan et al. describe the rescue of
monomeric circular forms of the AAV genome from muscles injected with
an rAAV (10). Interestingly, such circles could be used as
templates for the formation of head-to-tail arrays of the rAAV genome
by a rolling-circle replicative mechanism similar to the one described
elsewhere for herpesviruses (6). Rolling-circle replication
could be initiated through the interaction of a cruciform structure
formed by the ITR and a cellular endonuclease (39).
Whether these high-molecular-weight forms are integrated into the host
genome or are episomal remains to be elucidated. The integration of
rAAV, mostly as single copies, has been directly documented in cell
culture experiments, upon selection of the transduced cells (9,
17, 23, 30). Miao et al. have reported that, following rAAV
transduction of the liver, multiple copies of rAAV genomes are
associated with high-molecular-weight DNA in the megabase range, again
as head-to-tail concatemers (24). A direct association of
the vector sequences with the chromosomal DNA was suggested by in situ
hybridization on metaphase chromosomes from explanted hepatocytes
(24). However, direct evidence for integration of the rAAV
genome following in vivo administration, such as the identification of
junctions between rAAV and the host DNA, is still lacking. It remains
possible that, given the appropriate cellular milieu, the multimerized
vector DNA tightly associates with the chromosome and is constantly
replicated, thereby escaping degradation within the nucleus.
 |
ACKNOWLEDGMENTS |
We thank Anne Marie Douar and Antoine Kichler for discussions and
critical reading of the manuscript and Melinda Van Roey for animal care.
This work was supported by the Association Française contre les Myopathies.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Gene Therapy
Program, Genethon III, CNRS URA 1922, Evry, France. Phone: 33-1-69 47 29 64. Fax: 33-1-69 47 28 38. E-mail: odanos{at}genethon.fr.
 |
REFERENCES |
| 1.
|
Alexander, I. E.,
D. W. Russell, and A. D. Miller.
1994.
DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors.
J. Virol.
68:8282-8287[Abstract/Free Full Text].
|
| 2.
|
Alexander, I. E.,
D. W. Russell,
A. M. Spence, and A. D. Miller.
1996.
Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors.
Hum. Gene Ther.
7:841-850[Medline].
|
| 3.
|
Ausubel, F. M.,
R. Brent,
R. E. Kingston,
D. D. Moore,
J. G. Seidman,
J. A. Smith, and K. Struhl.
1992.
Short protocols in molecular biology, 2nd ed.
Greene Publishing Associates and John Wiley & Sons, New York, N.Y.
|
| 4.
|
Berns, K. I.
1990.
Parvoviridae and their replication, p. 1743-1764.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 2nd ed. Raven Press, New York, N.Y.
|
| 5.
|
Berns, K. I., and J. A. Rose.
1970.
Evidence for a single-stranded adenovirus-associated virus genome: isolation and separation of complementary single strands.
J. Virol.
5:693-699[Abstract/Free Full Text].
|
| 6.
|
Boehmer, P. E., and I. R. Lehman.
1997.
Herpes simplex virus DNA replication.
Annu. Rev. Biochem.
66:347-384[Medline].
|
| 7.
|
Clark, K. R.,
T. J. Sferra, and P. R. Johnson.
1997.
Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle.
Hum. Gene Ther.
8:659-669[Medline].
|
| 8.
|
Cullen, M. J., and D. N. Landon.
1994.
The normal ultrastructure of skeletal muscle, p. 87-131.
In
J. Walton, G. Karpati, and D. Hilton-Jones (ed.), Disorders of voluntary muscle, 6th ed. Churchill Livingstone, New York, N.Y.
|
| 9.
|
Duan, D.,
K. J. Fisher,
J. F. Burda, and J. F. Engelhardt.
1997.
Structural and functional heterogeneity of integrated recombinant AAV genomes.
Virus Res.
48:41-56[Medline].
|
| 10.
|
Duan, D.,
P. Sharma,
J. Yang,
Y. Yue,
L. Dudus,
Y. Zhang,
K. J. Fisher, and J. F. Engelhardt.
1998.
Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue.
J. Virol.
72:8568-8577[Abstract/Free Full Text].
|
| 11.
|
Ferrari, F. K.,
T. Samulski,
T. Shenk, and R. J. Samulski.
1996.
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors.
J. Virol.
70:3227-3234[Abstract].
|
| 12.
|
Fisher, K. J.,
G. P. Gao,
M. D. Weitzman,
R. De Matteo,
J. F. Burda, and J. M. Wilson.
1996.
Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis.
J. Virol.
70:520-532[Abstract].
|
| 13.
|
Fisher, K. J.,
K. Jooss,
J. Alston,
Y. Yang,
S. E. Haecker,
K. High,
R. Pathak,
S. E. Raper, and J. M. Wilson.
1997.
Recombinant adeno-associated virus for muscle directed gene therapy.
Nat. Med.
3:306-312[Medline].
|
| 14.
|
Flannery, J. G.,
S. Zolotukhin,
M. I. Vaquero,
M. M. LaVail,
N. Muzyczka, and W. W. Hauswirth.
1997.
Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus.
Proc. Natl. Acad. Sci. USA
94:6916-6921[Abstract/Free Full Text].
|
| 15.
|
Herzog, R. W.,
J. N. Hagstrom,
S. H. Kung,
S. J. Tai,
J. M. Wilson,
K. J. Fisher, and K. A. High.
1997.
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.
Proc. Natl. Acad. Sci. USA
94:5804-5809[Abstract/Free Full Text].
|
| 16.
|
Jooss, K.,
Y. Yang,
K. J. Fisher, and J. M. Wilson.
1998.
Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.
J. Virol.
72:4212-4223[Abstract/Free Full Text].
|
| 17.
|
Kearns, W. G.,
S. A. Afione,
S. B. Fulmer,
M. C. Pang,
D. Erikson,
M. Egan,
M. J. Landrum,
T. R. Flotte, and G. R. Cutting.
1996.
Recombinant adeno-associated virus (AAV-CFTR) vectors do not integrate in a site-specific fashion in an immortalized epithelial cell line.
Gene Ther.
3:748-755[Medline].
|
| 18.
|
Kessler, P. D.,
G. M. Podsakoff,
X. Chen,
S. A. McQuiston,
P. C. Colosi,
L. A. Matelis,
G. J. Kurtzman, and B. J. Byrne.
1996.
Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein.
Proc. Natl. Acad. Sci. USA
93:14082-14087[Abstract/Free Full Text].
|
| 19.
|
Koeberl, D. D.,
I. E. Alexander,
C. L. Halbert,
D. W. Russell, and A. D. Miller.
1997.
Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors.
Proc. Natl. Acad. Sci. USA
94:1426-1431[Abstract/Free Full Text].
|
| 20.
|
Koepke, J. A.
1991.
Practical laboratory hematology, p. 112-114.
Churchill Livingstone, New York, N.Y.
|
| 21.
|
Kotin, R. M.,
M. Siniscalco,
R. J. Samulski,
X. D. Zhu,
L. Hunter,
C. A. Laughlin,
S. McLaughlin,
N. Muzyczka,
M. Rocchi, and K. I. Berns.
1990.
Site-specific integration by adeno-associated virus.
Proc. Natl. Acad. Sci. USA
87:2211-2215[Abstract/Free Full Text].
|
| 22.
|
Mandel, R. J.,
S. K. Spratt,
R. O. Snyder, and S. E. Leff.
1997.
Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.
Proc. Natl. Acad. Sci. USA
94:14083-14088[Abstract/Free Full Text].
|
| 23.
|
McLaughlin, S. K.,
P. Collis,
P. L. Hermonat, and N. Muzyczka.
1988.
Adeno-associated virus general transduction vectors: analysis of proviral structures.
J. Virol.
62:1963-1973[Abstract/Free Full Text].
|
| 24.
|
Miao, C. H.,
R. O. Snyder,
D. B. Schowalter,
G. A. Patijn,
B. Donahue,
B. Winther, and M. A. Kay.
1998.
The kinetics of rAAV integration in the liver.
Nat. Genet.
19:13-15[Medline].
|
| 25.
|
Monahan, P. E.,
R. J. Samulski,
J. Tazelaar,
X. Xiao,
T. C. Nichols,
D. A. Bellinger,
M. S. Read, and C. E. Walsh.
1998.
Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
Gene Ther.
5:40-49[Medline].
|
| 26.
|
Murphy, J. E.,
S. Zhou,
K. Giese,
L. T. Williams,
J. A. Escobedo, and V. J. Dwarki.
1997.
Long-term correction of obesity and diabetes in genetically obese mice by a single intramuscular injection of recombinant adeno-associated virus encoding mouse leptin.
Proc. Natl. Acad. Sci. USA
94:13921-13926[Abstract/Free Full Text].
|
| 27.
|
Ponnazhagan, S.,
P. Mukherjee,
X. S. Wang,
K. Qing,
D. M. Kube,
C. Mah,
C. Kurpad,
M. C. Yoder,
E. F. Srou, and A. Srivastava.
1997.
Adeno-associated virus type 2-mediated transduction in primary human bone marrow-derived CD34+ hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation.
J. Virol.
71:8262-8267[Abstract].
|
| 28.
|
Qing, K.,
B. Khuntirat,
C. Mah,
D. M. Kube,
X. S. Wang,
S. Ponnazhagan,
S. Zhou,
V. J. Dwarki,
M. C. Yoder, and A. Srivastava.
1998.
Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo.
J. Virol.
72:1593-1599[Abstract/Free Full Text].
|
| 29.
|
Russell, D. W.,
I. E. Alexander, and A. D. Miller.
1995.
DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors.
Proc. Natl. Acad. Sci. USA
92:5719-5723[Abstract/Free Full Text].
|
| 30.
|
Rutledge, E. A., and D. W. Russell.
1997.
Adeno-associated virus vector junctions.
J. Virol.
71:8429-8436[Abstract].
|
| 31.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 32.
|
Samulski, R. J.,
L. S. Chang, and T. Shenk.
1989.
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.
J. Virol.
63:3822-3828[Abstract/Free Full Text].
|
| 33.
|
Snyder, R. O.,
C. H. Miao,
G. A. Patijn,
S. K. Spratt,
O. Danos,
D. Nagy,
A. M. Gown,
B. Winther,
L. Meuse,
L. K. Cohen,
A. R. Thompson, and M. A. Kay.
1997.
Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Nat. Genet.
16:270-276[Medline].
|
| 34.
|
Snyder, R. O.,
S. K. Spratt,
C. Lagarde,
D. Bohl,
B. Kaspar,
B. Sloan,
L. K. Cohen, and O. Danos.
1997.
Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice.
Hum. Gene Ther.
8:1891-1900[Medline].
|
| 35.
|
Snyder, R. O.,
X. Xiao, and R. J. Samulski.
1996.
Vectors for gene therapy: production of recombinant adeno-associated viral vectors, p. 12.1.1-12.1.24.
In
N. Dracopoli, et al. (ed.), Current protocols in human genetics. John Wiley & Sons, Inc., New York, N.Y.
|
| 36.
|
Summerford, C., and R. J. Samulski.
1998.
Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.
J. Virol.
72:1438-1445[Abstract/Free Full Text].
|
| 37.
|
Weitzman, M. D.,
S. R. Kyostio,
R. M. Kotin, and R. A. Owens.
1994.
Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.
Proc. Natl. Acad. Sci. USA
91:5808-5812[Abstract/Free Full Text].
|
| 38.
|
Xiao, X.,
J. Li, and R. J. Samulski.
1996.
Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.
J. Virol.
70:8098-8108[Abstract].
|
| 39.
|
Xiao, X.,
W. Xiao,
J. Li, and R. J. Samulski.
1997.
A novel 165-base-pair terminal repeat sequence is the sole cis requirement for the adeno-associated virus life cycle.
J. Virol.
71:941-948[Abstract].
|
| 40.
|
Zolotukhin, S.,
M. Potter,
W. W. Hauswirth,
J. Guy, and N. Muzyczka.
1996.
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells.
J. Virol.
70:4646-4654[Abstract].
|
Journal of Virology, March 1999, p. 1949-1955, Vol. 73, No. 3
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Penaud-Budloo, M., Le Guiner, C., Nowrouzi, A., Toromanoff, A., Cherel, Y., Chenuaud, P., Schmidt, M., von Kalle, C., Rolling, F., Moullier, P., Snyder, R. O.
(2008). Adeno-Associated Virus Vector Genomes Persist as Episomal Chromatin in Primate Muscle. J. Virol.
82: 7875-7885
[Abstract]
[Full Text]
-
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L., Danos, O.
(2004). Rescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping. Science
306: 1796-1799
[Abstract]
[Full Text]
-
Duan, D., Yue, Y., Engelhardt, J. F.
(2003). Consequences of DNA-Dependent Protein Kinase Catalytic Subunit Deficiency on Recombinant Adeno-Associated Virus Genome Circularization and Heterodimerization in Muscle Tissue. J. Virol.
77: 4751-4759
[Abstract]
[Full Text]
-
Schnepp, B. C., Clark, K. R., Klemanski, D. L., Pacak, C. A., Johnson, P. R.
(2003). Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle. J. Virol.
77: 3495-3504
[Abstract]
[Full Text]
-
Wang, F., Rendahl, K. G., Manning, W. C., Quiroz, D., Coyne, M., Miller, S. S.
(2003). AAV-Mediated Expression of Vascular Endothelial Growth Factor Induces Choroidal Neovascularization in Rat. IOVS
44: 781-790
[Abstract]
[Full Text]
-
Favre, D., Blouin, V., Provost, N., Spisek, R., Porrot, F., Bohl, D., Marme, F., Cherel, Y., Salvetti, A., Hurtrel, B., Heard, J.-M., Riviere, Y., Moullier, P.
(2002). Lack of an Immune Response against the Tetracycline-Dependent Transactivator Correlates with Long-Term Doxycycline-Regulated Transgene Expression in Nonhuman Primates after Intramuscular Injection of Recombinant Adeno-Associated Virus. J. Virol.
76: 11605-11611
[Abstract]
[Full Text]
-
Chamberlain, J. S.
(2002). Gene therapy of muscular dystrophy. Hum Mol Genet
11: 2355-2362
[Abstract]
[Full Text]
-
Aikawa, R., Huggins, G. S., Snyder, R. O.
(2002). Cardiomyocyte-specific Gene Expression Following Recombinant Adeno-associated Viral Vector Transduction. J. Biol. Chem.
277: 18979-18985
[Abstract]
[Full Text]
-
Bantel-Schaal, U., Hub, B., Kartenbeck, J.
(2002). Endocytosis of Adeno-Associated Virus Type 5 Leads to Accumulation of Virus Particles in the Golgi Compartment. J. Virol.
76: 2340-2349
[Abstract]
[Full Text]
-
Zentilin, L., Marcello, A., Giacca, M.
(2001). Involvement of Cellular Double-Stranded DNA Break Binding Proteins in Processing of the Recombinant Adeno-Associated Virus Genome. J. Virol.
75: 12279-12287
[Abstract]
[Full Text]
-
Raben, N., Lu, N., Nagaraju, K., Rivera, Y., Lee, A., Yan, B., Byrne, B., Meikle, P.J., Umapathysivam, K., Hopwood, J.J., Plotz, P.H.
(2001). Conditional tissue-specific expression of the acid {alpha}-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet
10: 2039-2047
[Abstract]
[Full Text]
-
Ponnazhagan, S., Curiel, D. T., Shaw, D. R., Alvarez, R. D., Siegal, G. P.
(2001). Adeno-associated Virus for Cancer Gene Therapy. Cancer Res.
61: 6313-6321
[Full Text]
-
Nakai, H., Yant, S. R., Storm, T. A., Fuess, S., Meuse, L., Kay, M. A.
(2001). Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction In Vivo. J. Virol.
75: 6969-6976
[Abstract]
[Full Text]
-
Sarukhan, A., Camugli, S., Gjata, B., von Boehmer, H., Danos, O., Jooss, K.
(2001). Successful Interference with Cellular Immune Responses to Immunogenic Proteins Encoded by Recombinant Viral Vectors. J. Virol.
75: 269-277
[Abstract]
[Full Text]
-
Su, H., Lu, R., Kan, Y. W.
(2000). Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc. Natl. Acad. Sci. USA
10.1073/pnas.250488097v1
[Abstract]
[Full Text]
-
Nakai, H., Storm, T. A., Kay, M. A.
(2000). Recruitment of Single-Stranded Recombinant Adeno-Associated Virus Vector Genomes and Intermolecular Recombination Are Responsible for Stable Transduction of Liver In Vivo. J. Virol.
74: 9451-9463
[Abstract]
[Full Text]
-
Haberman, R. P., McCown, T. J., Samulski, R. J.
(2000). Novel Transcriptional Regulatory Signals in the Adeno-Associated Virus Terminal Repeat A/D Junction Element. J. Virol.
74: 8732-8739
[Abstract]
[Full Text]
-
Tattersall, P.
(2000). The persistence of alien genomes. Proc. Natl. Acad. Sci. USA
97: 6239-6241
[Full Text]
-
Malik, A. K., Monahan, P. E., Allen, D. L., Chen, B.-G., Samulski, R. J., Kurachi, K.
(2000). Kinetics of Recombinant Adeno-Associated Virus-Mediated Gene Transfer. J. Virol.
74: 3555-3565
[Abstract]
[Full Text]
-
Miao, C. H., Nakai, H., Thompson, A. R., Storm, T. A., Chiu, W., Snyder, R. O., Kay, M. A.
(2000). Nonrandom Transduction of Recombinant Adeno-Associated Virus Vectors in Mouse Hepatocytes In Vivo: Cell Cycling Does Not Influence Hepatocyte Transduction. J. Virol.
74: 3793-3803
[Abstract]
[Full Text]
-
Yang, J., Zhou, W., Zhang, Y., Zidon, T., Ritchie, T., Engelhardt, J. F.
(1999). Concatamerization of Adeno-Associated Virus Circular Genomes Occurs through Intermolecular Recombination. J. Virol.
73: 9468-9477
[Abstract]
[Full Text]
-
Su, H., Lu, R., Kan, Y. W.
(2000). Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc. Natl. Acad. Sci. USA
97: 13801-13806
[Abstract]
[Full Text]